Home > Haematology > ASH 2019 > Venous Thromboembolism > 20-Year follow-up of imatinib in chronic myeloid leukaemia after failure with interferon

20-Year follow-up of imatinib in chronic myeloid leukaemia after failure with interferon

Presented By
Dr Maria Vazquez, MD Anderson Cancer Center, Houston, USA
Conference
ASH 2019
In the longest follow-up of patients on imatinib therapy ever reported, Dr Maria Vazquez (MD Anderson Cancer Center, Houston, USA) and colleagues demonstrated the long-term benefit of the tyrosine kinase inhibitor imatinib in patients with chronic phase chronic myeloid leukaemia (CML), after these patients no longer responded to interferon (IFN) treatment [1]. In this single-institution study, 154 patients whose disease was refractory to IFN in 1999/2000 were switched to 400 mg imatinib. The majority of patients who passed away (36%), were lost to follow-up (29%), or switched to a different tyrosine kinase inhibitor (37%). The purpose of this study was to evaluate the long-term effects of imatinib on CML disease response. Dr Vasquez reported the available intention-to-treat responses for 63 patients, with a median follow-up of 232 months. The median overall survival was 51%. Major cytogenic response was reported in 35% of these patients at 3 months,...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on